PRIMAXIN
Total Payments
$1.7M
Transactions
61
Doctors
1
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $134,739 | 5 | 0 |
| 2022 | $95,016 | 1 | 0 |
| 2021 | $121,425 | 1 | 0 |
| 2020 | $373,950 | 18 | 0 |
| 2019 | $365,471 | 17 | 0 |
| 2018 | $505,125 | 15 | 0 |
| 2017 | $87,894 | 4 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 60 | 99.9% |
| Travel and Lodging | $2,401 | 1 | 0.1% |
Payments by Type
Research
$1.7M
60 transactions
General
$2,401
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| In vitro Potency and Pharmacodynamic Activity of Imipenem-Relebactam Alone and When Combined with Other Antibiotics against Pseudomonas aeruginosa | Merck Sharp & Dohme Corporation | $173,175 | 0 |
| In Vivo Activity of the Human-Simulated Regimens of Imipenem alone and in Combination with Relebactam against Pseudomonas aeruginosa in the Murine Thigh Infection Model | Merck Sharp & Dohme Corporation | $135,200 | 0 |
| STUDY NAMEAn Open-label Pharmacokinetic Study of Imipenem-Relebactam in Critically-Ill Patients with Augmented Renal Clearance | Merck Sharp & Dohme Corporation | $121,425 | 0 |
| Clinical and genetic characterization of carbapenem-resistant Enterobacteriaceae in South Texas | Merck Sharp & Dohme Corporation | $117,169 | 0 |
| Preclinical Evaluation of the Vancomycin Dose-Nephrotoxicity Relationship when Combined with Piperacillin,Tazobactam or Imipenem-Cilastatin,Relebactam MK-7655A | Merck Sharp & Dohme Corporation | $107,758 | 0 |
| Comparative In Vitro Activity of Imipenem-Relebactam against Pediatric Drug-Resistant Gram Negative Isolates from three pediatric hospitals | Merck Sharp & Dohme Corporation | $107,338 | 0 |
| An Open-label Pharmacokinetic Study of Imipenem-Relebactam in Critically-Ill Patients with Augmented Renal Clearance | Merck Sharp & Dohme LLC | $95,016 | 0 |
| Susceptibility to imipenem,relebactam, meropenem,vaborbactam, and comparator agents vs. clonal background among carbapenem-resistant Escherichia coli clinical isolates from Minnesota and the United States | Merck Sharp & Dohme Corporation | $85,218 | 0 |
| Activity of imipenem-relebactam in diverse emerging CRE a combined epidemiological and genomics approach | Merck Sharp & Dohme Corporation | $83,593 | 0 |
| In-vitro susceptibility and genomic testing of recent clinical gram-negative isolates recovered from cancer patients for imipenem-cilastatin-relebactam MK-7655 and comparator agents | Merck Sharp & Dohme Corporation | $69,667 | 0 |
| An Open-label Pharmacokinetic Study of Imipenem-Relebactam in Critically-Ill Patients with Augmented Renal Clearance | Merck Sharp & Dohme Corporation | $65,114 | 0 |
| Defining the clinical impact of imipenem-relebactam against Gram-negative bacteria possessing class A and C -lactamases Susceptibility testing and biochemistry | Merck Sharp & Dohme Corporation | $62,500 | 0 |
| Defining the clinical impact of imipenem-relebactam against Gram-negative bacteria possessing class A and C beta-lactamases Susceptibility testing and biochemistry | Merck Sharp & Dohme Corporation | $62,500 | 0 |
| STUDY NAME#Determining the pharmacodynamic activity of imipenem-relebactam in combination with fosfomycin to treat multi-drug resistant Pseudomonas aeruginosa | Merck Sharp & Dohme LLC | $40,678 | 0 |
| Synergistic activity of aztreonam in combination with imipenem-relebactam against serine- and metallo-beta-lactamase-producing Escherichia coli | Merck Sharp & Dohme Corporation | $35,655 | 0 |
| Leveraging the high potency of imipenem,relebactam against carbapenem-resistant pathogens as a potential novel streamlined treatment option for patients co-infected with multiple carbapenem-resistant organisms to improve outcome. | Merck Sharp & Dohme Corporation | $35,337 | 0 |
| Relebactam Clearance During Continuous Renal Replacement Therapy CRRT An Ex vivo Investigation | Merck Sharp & Dohme Corporation | $33,545 | 0 |
| Antimicrobial susceptibility of Gram-negative bacilli to imipenem-relebactam | Merck Sharp & Dohme Corporation | $31,986 | 0 |
| STUDY NAME#A comparative analysis on the frequency of resistance to imipenem-relebactam vs. ceftazidime-avibactam in Burkholderia cepacia complex | Merck Sharp & Dohme LLC | $31,200 | 0 |
| A novel combination of beta-lactamase inhibitor relebactam in combination with imipenem to combat MDR infections in high-risk patients in vitro mechanisms and epidemiology | Merck Sharp & Dohme Corporation | $29,986 | 0 |
Top Doctors Receiving Payments for PRIMAXIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $1.7M | 60 |
| , MD | General Acute Care Hospital | New York, NY | $2,401 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $1.5M
- Merck Sharp & Dohme LLC $229,755
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 1
- Transactions 61
About PRIMAXIN
PRIMAXIN is a drug associated with $1.7M in payments to 1 healthcare providers, recorded across 61 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $134,739 was paid across 5 transactions to 0 doctors.
The most common payment nature for PRIMAXIN is "Unspecified" ($1.7M, 99.9% of total).
PRIMAXIN is associated with 20 research studies, including "In vitro Potency and Pharmacodynamic Activity of Imipenem-Relebactam Alone and When Combined with Other Antibiotics against Pseudomonas aeruginosa" ($173,175).